Cancer Research and Treatment

Original Articles

Lung and Thoracic cancer

Association between Antipsychotic Drug and Survival in Patients with Lung Cancer Treated with Chemoradiotherapy: A Nationwide Korean Cohort Study: Dong-Yun Kim, In Gyu Hwang, Sun Mi Kim, Dae Ryong Kang, Tae-Hwa Go, Se Hwa Hong, Shin Young Park, Hyunho Lee, Jin Hwa Choi; Cancer Res Treat. 2025;57(4):1030-1039. Published online February 6, 2025; DOI: https://doi.org/10.4143/crt.2024.554

Abstract PDF Supplementary Material PubReader ePub: Purpose
Antipsychotic drugs (APDs) can be used to relieve psychological symptoms in patients with cancer. We investigated the nationwide use of APDs during concurrent chemoradiotherapy (CCRT) for patients with lung cancer and its association with overall survival (OS).
Materials and Methods
The National Health Service database was used in this retrospective cohort study. Patients diagnosed with lung cancer between 2010 and 2020 who received cisplatin-based CCRT were included. The APDs included in the analysis were aripiprazole, quetiapine, olanzapine, risperidone, haloperidol, and chlorpromazine, and the APD prescription details included prescription time, dosage, and duration.
Results
Among the 23,099 patients with lung cancer treated with CCRT, 2,662 (11.5%) took APDs concurrently. Quetiapine (47.3%) and chlorpromazine (36.6%) were the frequently prescribed APDs. In the univariate analysis, patients prescribed APDs during CCRT had a significantly worse OS than those who did not take APDs. The 2-year OS rates for APD (+) and APD (–) patients were 20.4% and 36.4%, respectively (p < 0.001). Multivariable analyses revealed that APD prescription, male, age > 80 years, and comorbidities, such as hypertension, myocardial infarction, and depressive disorder, significantly influenced OS. In patients who used APDs during CCRT, APD prescription timing (pre-CCRT vs. during CCRT), dosage (low vs. high) and duration (within 6 months vs. over 6 months) had no significant difference.
Conclusion
Overall, 11.5% of patients with lung cancer used APDs during CCRT. Patients who used APDs during CCRT had poorer survival than those who did not. Further studies are required to elucidate the effects of APDs on patients with cancer.

3,999 View
122 Download

Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy: Jung Ran Choi, Jeong-Oh Kim, Dae Ryong Kang, Jung-Young Shin, Xiang Hua Zhang, Ji Eun Oh, Ji-Young Park, Kyoung-Ah Kim, Jin-Hyoung Kang; Cancer Res Treat. 2015;47(3):509-517. Published online December 16, 2014; DOI: https://doi.org/10.4143/crt.2014.012

Abstract PDF PubReader ePub

Purpose
Dose-limiting toxicities of docetaxel are widely considered to be neutropenia, anemia, skin toxicity, and nausea. One of the factors that limit the use of docetaxel is its unpredictability of inter-individual variation in toxicity. Materials and Methods In order to identify the genetic factors that affect the risk of docetaxel-induced toxicities, we recruited patients who received docetaxel chemotherapy. We genotyped 92 patients with single-nucleotide polymorphisms (SNPs) in 5 genes: CYP3A4 (CYP3A4*1B, CYP3A4*18, and CYP3A4*3), CYP3A5 (CYP3A5*2 and CYP3A5*3), ABCB1 (C1236T, G2677G/T, and C3435T), SLCO1B3 (rs11045585), and ABCC2 (rs12762549). Results Out of 92 patients, 70 had grade 3 or 4 neutropenia; 4 had grade 1 or 2; and 18 had no toxicity (76.1%, 4.3%, and 19.6%, respectively). The findings of the SNP analysis showed that patients with TT genotype of ABCB1 3435C>T polymorphism showed significantly higher risk of neutropenia and anemia (p=0.029 and p=0.044, respectively). There were significant associations between docetaxel-induced leucopenia and 2677G/T of ABCB1 and rs12762549 of ABCC2 (p=0.025 and p=0.028, respectively). In a multivariate analysis, we observed that patients carrying 2677G>T in ABCB1might be associated with higher risk of chemo-resistance when treated with docetaxel (odds ratio [OR], 6.48; confidence interval, 1.92 to 21.94; p=0.003). In a subgroup analysis of non-small cell lung cancer patients, a significant association of tumor response with G2677T/A (OR, 4.54) in ABCB1 and SLCO1B3 (OR, 9.44) was observed. Conclusion Our data suggest that ABCB1 (2677G/T) and SLCO1B3 (rs11055585) might be major genetic predictors of docetaxel-related toxicities in patients receiving docetaxel chemotherapy

Citations

Citations to this article as recorded by

NFE2L2 rs35652124C>T polymorphism predicts Grade 4 neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and fluorouracil chemotherapy: results from exploratory and validation cohorts
Hisanaga Nomura, Takaya Suzuki, Takashi Kojima, Kunihiko Itoh, Daiki Tsuji
Cancer Chemotherapy and Pharmacology.2026;[Epub] CrossRef
Pharmacogenomic Alterations in High-Risk Triple-Negative Breast Cancer and Its Adverse Drug Reactions: A Cross-Sectional and Observational Study
Priyanka Namdev, Vignesh Krishnasamy, Andrew Vanllawma, Lalengkimi Ralte, Lalawmpuii Pachuau, Zothankima Bawitlung, Lalfakzuala Khenglawt, Lalsangmawia Khawlhring, Ashok K. Varma, Nachimuthu Senthil Kumar
Current Pharmacogenomics and Personalized Medicine.2026;[Epub] CrossRef
Towards personalized prostate cancer treatment with docetaxel in indonesia: a pharmacogenomics perspective
Jekmal Malau, Siti Rohmah, Nanda Diva Meilani, Anastasia Aliesa Hermosaningtyas, Ahsanal Kasasiah, Ratika Rahmasari, Heri Setiawan, Fahri Azhari Hasby, Muhareva Raekiansyah, Rosario Trijuliamos Manalu
Egyptian Journal of Medical Human Genetics.2025;[Epub] CrossRef
Non-coding RNAs: Emerging contributors to chemoresistance in chronic myeloid leukemia
Laya Ghadyani nejhad, Mahsa Sohani, Nasrin Alizad Ghandforoush, Mohsen Nikbakht, Saeed Mohammadi, Mohammad Vaezi, Shahrbano Rostami, Bahram Chahardouli
Leukemia Research Reports.2025; 23: 100513. CrossRef
Impact of low BMI and ABCC2 genotype on the clinical response of sequential anthracycline-taxane chemotherapy receiving breast cancer patients: a hospital-based study
Tanuma Mistry, Sanghamitra Sengupta, R. Suresh Kumar, Nisha Thakur, Partha Nath, Neyaz Alam, Vilas D. Nasare
The Pharmacogenomics Journal.2025;[Epub] CrossRef
Polymorphism of Transporter Genes Contributes to Variations in Treatment Outcomes and Adverse Events in Platinum Based- Chemotherapy- Treated Oral Cancer Patients
Pranab Kumar Sahoo, Tanuma Mistry, Sushmita Ghosh, Ranita Pal, Sutapa Mahata, Sinjini Sarkar, Trisha Choudhury, Sriparna Datta, R Suresh Kumar, Anup Kumar Bhowmick, Partha Nath, Kalyan Kusum Mukherjee, Vilas D. Nasare
Precision Oncogenomics.2024;[Epub] CrossRef
The Role of Pharmacogenetic-Based Pharmacokinetic Analysis in Precise Breast Cancer Treatment
Xinyu Wu, Huihua Xiong
Pharmaceutics.2024; 16(11): 1407. CrossRef
Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum‐based doublet chemotherapy
Parul Sharma, Navneet Singh, Siddharth Sharma
Journal of Biochemical and Molecular Toxicology.2023;[Epub] CrossRef
Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment
Yoshitaka Saito, Shinya Tamaki, Daisuke Hirate, Shinya Takada, Kenta Takahashi, Yoh Takekuma, Jun Sakakibara-Konishi, Yasushi Shimizu, Ichiro Kinoshita, Mitsuru Sugawara
Scientific Reports.2023;[Epub] CrossRef
Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis
Mingrui Yan, Xiaoyu Fan, Hongyanhua Si, Xiaoyu Wang, Zhe Wang, Zhen Wang, Xin Lv, Hang Yin, Yanyan Jia, Lili Jiang, Yangliu Xia, Yong Liu
Cancer Chemotherapy and Pharmacology.2022; 89(2): 173. CrossRef
Genetic Epidemiology of Medication Safety and Efficacy Related Variants in the Central Han Chinese Population With Whole Genome Sequencing
Junbo Tian, Jing Zhang, Zengguang Yang, Shuaisheng Feng, Shujuan Li, Shiqi Ren, Jianxiang Shi, Xinyue Hou, Xia Xue, Bei Yang, Hongen Xu, Jiancheng Guo
Frontiers in Pharmacology.2022;[Epub] CrossRef
Polymorphisms in solute carrier genes ( SLC19A1 , SLCO1B1 , and SLCO1B3 ) predicts sur
Parul Sharma, Navneet Singh, Siddharth Sharma
Journal of Clinical Pharmacy and Therapeutics.2022; 47(12): 2049. CrossRef
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation
Anne T. Nies, Elke Schaeffeler, Matthias Schwab
Pharmacology & Therapeutics.2022; 238: 108268. CrossRef
Knowledge, attitude, future expectations and perceived barriers of medical students and physicians regarding pharmacogenomics in Jordan
Abdallah Alzoubi, Hashem Kanaan, Dua'a Alhazaimeh, Salam Gharaibeh, Tareq L. Mukattash, Khalid Kheirallah
International Journal of Clinical Practice.2021;[Epub] CrossRef
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel
Caterina Vivaldi, Stefania Crucitta, Silvia Catanese, Federico Cucchiara, Elena Arrigoni, Irene Pecora, Eleonora Rofi, Lorenzo Fornaro, Francesca Salani, Valentina Massa, Enrico Vasile, Riccardo Morganti, Romano Danesi, Marzia Del Re
The Pharmacogenomics Journal.2021; 21(2): 233. CrossRef
Investigation of the 1249G>A Genetic Variation of ABCC2 Drug Transporter Gene in the Turkish Population
Zuhal UCKUN SAHİNOGULLARİ
Dicle Tıp Dergisi.2021; 48(1): 72. CrossRef
Pharmacogenetics–Based Preliminary Algorithm to Predict the Incidence of Infection in Patients Receiving Cytotoxic Chemotherapy for Hematological Malignancies: A Discovery Cohort
Matias F. Martinez, Enzo Alveal, Tomas G. Soto, Eva I. Bustamante, Fernanda Ávila, Shrikant I. Bangdiwala, Ivonne Flores, Claudia Monterrosa, Ricardo Morales, Nelson M. Varela, Alison E. Fohner, Luis A. Quiñones
Frontiers in Pharmacology.2021;[Epub] CrossRef
Genetic associations of docetaxel‐based chemotherapy‐induced myelosuppression in Chinese Han population
Weihua Ren, Chenxi Zhou, Yedong Liu, Keli Su, Li Jia, Luan Chen, Mo Li, Jingsong Ma, Wei Zhou, Suli Zhang, Di Zhang, Zhiliang Cong, Xuecai Niu, Shengui Zhang, Lu Shen, Cong Huai, Xiaofang Sun, Guorong Li, Shengying Qin, Liang Guo
Journal of Clinical Pharmacy and Therapeutics.2020; 45(2): 354. CrossRef
ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy
Hisanaga Nomura, Daiki Tsuji, Ken Demachi, Nobuo Mochizuki, Haruki Matsuzawa, Tomonori Yano, Hiroyuki Daiko, Satoshi Fujii, Takashi Kojima, Kunihiko Itoh, Toshikatsu Kawasaki
Cancer Chemotherapy and Pharmacology.2020; 86(2): 315. CrossRef
Association of a genetic variant in ATP‐binding cassette sub‐family B member 1 gene with poor prognosis in patients with squamous cell carcinoma of the esophagus
Azam Rastgar‐Moghadam, Mehrane Mehramiz, Soodabeh Shahidsales, Malihe Entezari, Seyed Mahdi Hassanian, Sahar Talebian, Mahnaz Nourbakhsh, Gordon A. Ferns, Amir Avan
IUBMB Life.2019; 71(9): 1252. CrossRef
Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology
Rachael R. Schulte, Richard H. Ho
Molecular Pharmacology.2019; 95(5): 490. CrossRef
The Emerging Role of the SLCO1B3 Protein in Cancer Resistance
Ruipu Sun, Ying Ying, Zhimin Tang, Ting Liu, Fuli Shi, Huixia Li, Taichen Guo, Shibo Huang, Ren Lai
Protein & Peptide Letters.2019; 27(1): 17. CrossRef
Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort
Kazuki Sone, Tetsuya Oguri, Takehiro Uemura, Akira Takeuchi, Satoshi Fukuda, Osamu Takakuwa, Ken Maeno, Kensuke Fukumitsu, Yoshihiro Kanemitsu, Hirotsugu Ohkubo, Masaya Takemura, Yutaka Ito, Akio Niimi
BMC Cancer.2019;[Epub] CrossRef
Influence of the ABCB1 polymorphisms on the response to Taxane-containing chemotherapy: a systematic review and meta-analysis
Qi Jiang, Meizhen Xu, Yina Liu, Yudi Chen, Jiarong Feng, Xuelin Wang, Shuang Liang, Dan Li, Xiaoqin Yang
Cancer Chemotherapy and Pharmacology.2018; 81(2): 315. CrossRef
SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand
Raffaele Palmirotta, Claudia Carella, Erica Silvestris, Mauro Cives, Stefania Luigia Stucci, Marco Tucci, Domenica Lovero, Franco Silvestris
Oncotarget.2018; 9(38): 25355. CrossRef
Advances and challenges in hereditary cancer pharmacogenetics
Ingolf Cascorbi, Anneke Nina Werk
Expert Opinion on Drug Metabolism & Toxicology.2017; 13(1): 73. CrossRef
Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients
Guillermo Gervasini, Carlos Jara, Clara Olier, Nuria Romero, Ruth Martínez, Juan Antonio Carrillo
British Journal of Clinical Pharmacology.2017; 83(3): 562. CrossRef
Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with breast cancer
Delmy Oliva, Mats Nilsson, Bengt-Åke Andersson, Lena Sharp, Freddi Lewin, Nongnit Laytragoon-Lewin
Clinical and Translational Radiation Oncology.2017; 2: 1. CrossRef
Reacciones cutáneas a fármacos en el paciente con leucemia/linfoma
Mar Llamas-Velasco, Pedro Rodríguez-Jiménez, Pablo Chicharro, Javier Sánchez-Pérez
Piel.2017; 32(9): 548. CrossRef
Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy
Annelot G.J. van Rossum, Marleen Kok, Danielle McCool, Mark Opdam, Nienke C. Miltenburg, Ingrid A.M. Mandjes, Elise van Leeuwen-Stok, Alex L.T. Imholz, Johanneke E.A. Portielje, Monique M.E.M. Bos, Aart van Bochove, Erik van Werkhoven, Marjanka K. Schmidt
Oncotarget.2017; 8(69): 113531. CrossRef
Efflux Transporter Variants as Predictors of Drug Toxicity in Lung Cancer Patients: Systematic Review and Meta-Analysis
Zoulikha M Zaïr, Donald RJ Singer
Pharmacogenomics.2016; 17(9): 1089. CrossRef
Influx Transporter Variants as Predictors of Cancer Chemotherapy-Induced Toxicity: Systematic Review and Meta-Analysis
Zoulikha M Zaïr, Donald RJ Singer
Pharmacogenomics.2016; 17(10): 1189. CrossRef
Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature
Stefan Wolking, Elke Schaeffeler, Holger Lerche, Matthias Schwab, Anne T. Nies
Clinical Pharmacokinetics.2015; 54(7): 709. CrossRef
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer
Thomas Melchardt, Clemens Hufnagl, Teresa Magnes, Lukas Weiss, Georg Hutarew, Daniel Neureiter, Alexander Schlattau, Gerhard Moser, Alexander Gaggl, Wolfgang Tränkenschuh, Richard Greil, Alexander Egle
BMC Cancer.2015;[Epub] CrossRef
Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review
C.N. Frederiks, S.W. Lam, H.J. Guchelaar, E. Boven
Cancer Treatment Reviews.2015; 41(10): 935. CrossRef

17,342 View
155 Download
39 Web of Science
35 Crossref

First
Prev
Page of 1
Next
Last

Search